Literature DB >> 20227752

Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome.

Iusta Caminha, Thomas A Fleisher, Ronald L Hornung, Janet K Dale, Julie E Niemela, Susan Price, Joie Davis, Katie Perkins, Kennichi C Dowdell, Margaret R Brown, V Koneti Rao, João Bosco Oliveira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20227752      PMCID： PMC3412519          DOI： 10.1016/j.jaci.2009.12.983

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  8 in total

1.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

Authors:  C E Jackson; R E Fischer; A P Hsu; S M Anderson; Y Choi; J Wang; J K Dale; T A Fleisher; L A Middelton; M C Sneller; M J Lenardo; S E Straus; J M Puck
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

2.  Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.

Authors:  I J Fuss; W Strober; J K Dale; S Fritz; G R Pearlstein; J M Puck; M J Lenardo; S E Straus
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

3.  Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome.

Authors:  J J Bleesing; M R Brown; S E Straus; J K Dale; R M Siegel; M Johnson; M J Lenardo; J M Puck; T A Fleisher
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

4.  Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression.

Authors:  U Lopatin; X Yao; R K Williams; J J Bleesing; J K Dale; D Wong; J Teruya-Feldstein; S Fritz; M R Morrow; I Fuss; M C Sneller; M Raffeld; T A Fleisher; J M Puck; W Strober; E S Jaffe; S E Straus
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

5.  FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.

Authors:  Aude Magerus-Chatinet; Marie-Claude Stolzenberg; Maria S Loffredo; Bénédicte Neven; Catherine Schaffner; Nicolas Ducrot; Peter D Arkwright; Brigitte Bader-Meunier; José Barbot; Stéphane Blanche; Jean-Laurent Casanova; Marianne Debré; Alina Ferster; Claire Fieschi; Benoit Florkin; Claire Galambrun; Olivier Hermine; Olivier Lambotte; Eric Solary; Caroline Thomas; Francoise Le Deist; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  Blood       Date:  2009-01-27       Impact factor: 22.113

6.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

Authors:  João B Oliveira; Nicolas Bidère; Julie E Niemela; Lixin Zheng; Keiko Sakai; Cynthia P Nix; Robert L Danner; Jennifer Barb; Peter J Munson; Jennifer M Puck; Janet Dale; Stephen E Straus; Thomas A Fleisher; Michael J Lenardo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

Review 8.  Genetic disorders of programmed cell death in the immune system.

Authors:  Nicolas Bidère; Helen C Su; Michael J Lenardo
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527
  8 in total
  36 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

3.  Autoimmune lymphoproliferative syndrome: a multifactorial disorder.

Authors:  Frédéric Rieux-Laucat; Aude Magerus-Chatinet
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

4.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Authors:  Julie E Niemela; Lianghao Lu; Thomas A Fleisher; Joie Davis; Iusta Caminha; Marc Natter; Laurel A Beer; Kennichi C Dowdell; Stefania Pittaluga; Mark Raffeld; V Koneti Rao; João B Oliveira
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

5.  Gene defects in the soma: some get it and some don't!

Authors:  Bernice Lo; Michael J Lenardo
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 6.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Pu Li; Ping Huang; Ye Yang; Mu Hao; Hongwei Peng; Fei Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

7.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

Review 8.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

9.  Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans.

Authors:  Hye Sun Kuehn; Julie E Niemela; Andreia Rangel-Santos; Mingchang Zhang; Stefania Pittaluga; Jennifer L Stoddard; Ashleigh A Hussey; Moses O Evbuomwan; Debra A Long Priel; Douglas B Kuhns; C Lucy Park; Thomas A Fleisher; Gulbu Uzel; João B Oliveira
Journal:  Blood       Date:  2013-02-21       Impact factor: 22.113

10.  Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.

Authors:  Christian Klemann; Myrian Esquivel; Aude Magerus-Chatinet; Myriam R Lorenz; Ilka Fuchs; Nathalie Neveux; Martin Castelle; Jan Rohr; Claudia Bettoni da Cunha; Martin Ebinger; Robin Kobbe; Bernhard Kremens; Florian Kollert; Eleonora Gambineri; Kai Lehmberg; Markus G Seidel; Kathrin Siepermann; Thomas Voelker; Volker Schuster; Sigune Goldacker; Klaus Schwarz; Carsten Speckmann; Capucine Picard; Alain Fischer; Frederic Rieux-Laucat; Stephan Ehl; Anne Rensing-Ehl; Benedicte Neven
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.